Eledon Pharmaceuticals (ELDN) Liabilities and Shareholders Equity (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Liabilities and Shareholders Equity of $146.7 million for Q1 2026, down 9.08% year-on-year from $161.3 million in Q1 2025, and down 13.22% on a QoQ basis from $169.0 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $146.7 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 9.08% year-over-year to $146.7 million; the trailing twelve-month figure through Mar 2026 stood at $590.4 million (up 2.91% YoY), and the FY2025 full-year result was $169.0 million, down 4.73% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $146.7 million, down from $169.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $177.4 million in Q4 2024 and bottomed at $80.8 million in Q1 2024.
- The 5-year median for Liabilities and Shareholders Equity is $129.9 million (2025), against an average of $128.1 million.
- The widest annual swing landed in 2023, when Liabilities and Shareholders Equity slumped 49.0%; it then soared 99.59% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $92.8 million in 2022, then fell by 4.02% to $89.1 million in 2023, then soared by 99.18% to $177.4 million in 2024, then declined by 4.73% to $169.0 million in 2025, then fell by 13.22% to $146.7 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $146.7 million (Q1 2026), $169.0 million (Q4 2025), and $129.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 146.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 146.67 Mn |
| Dec 31, 2025 | 169.01 Mn |
| Sep 30, 2025 | 129.86 Mn |
| Jun 30, 2025 | 144.91 Mn |
| Mar 31, 2025 | 161.31 Mn |
| Dec 31, 2024 | 177.41 Mn |
| Sep 30, 2024 | 114.58 Mn |
| Jun 30, 2024 | 120.48 Mn |
| Mar 31, 2024 | 80.82 Mn |
| Dec 31, 2023 | 89.07 Mn |
| Sep 30, 2023 | 96.07 Mn |
| Jun 30, 2023 | 106.79 Mn |
| Mar 31, 2023 | 82.31 Mn |
| Dec 31, 2022 | 92.79 Mn |
| Sep 30, 2022 | 149.59 Mn |
| Jun 30, 2022 | 154.71 Mn |
| Mar 31, 2022 | 161.38 Mn |
| Dec 31, 2021 | 170.55 Mn |
| Sep 30, 2021 | 177.17 Mn |
| Jun 30, 2021 | 184.31 Mn |
| Mar 31, 2021 | 191.68 Mn |
| Dec 31, 2020 | 197.19 Mn |
| Sep 30, 2020 | 192.59 Mn |
| Jun 30, 2020 | 10.50 Mn |
| Mar 31, 2020 | 13.72 Mn |
| Dec 31, 2019 | 10.93 Mn |
| Sep 30, 2019 | 15.22 Mn |
| Jun 30, 2019 | 18.22 Mn |
| Mar 31, 2019 | 13.45 Mn |
| Dec 31, 2018 | 17.03 Mn |
| Sep 30, 2018 | 19.93 Mn |
| Jun 30, 2018 | 22.97 Mn |
| Mar 31, 2018 | 25.92 Mn |
| Dec 31, 2017 | 20.89 Mn |
| Sep 30, 2017 | 23.02 Mn |
| Jun 30, 2017 | 26.84 Mn |
| Mar 31, 2017 | 25.83 Mn |
| Dec 31, 2016 | 1.20 Mn |
| Sep 30, 2016 | 36.72 Mn |
| Jun 30, 2016 | 46.86 Mn |
| Mar 31, 2016 | 57.71 Mn |
| Dec 31, 2015 | 67.97 Mn |
| Sep 30, 2015 | 77.61 Mn |
| Jun 30, 2015 | 87.41 Mn |
| Mar 31, 2015 | 96.65 Mn |
| Dec 31, 2014 | 107.74 Mn |
| Sep 30, 2014 | 106.98 Mn |
| Dec 31, 2013 | 32.29 Mn |